Given that most men who present with erectile dysfunction (ED) are likely to be treated with oral therapy in the first instance, their diagnosis and investigation should reflect this. The objectives of this assessment should focus on identification of important risk factors for ED, such as diabetes, hypertension and hyperlipidaemia and on those (few) men who have curable ED. As such there are a number of baseline tests that should be done in all patients, with specialised investigations restricted to a few men.
Get full access to this article
View all access options for this article.
References
1.
RosenR.C., RileyA., WagnerG., OsterlohI., KirkpatrickJ., MishraA.The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 1997; 49:822–830.
2.
RosenR.C., CappelleriJ.C., SmithM.D., LipskyJ., PenaB.M.Development of evaluation of an abridged, 5-item version of the International Index of Erectile Functin (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impo Res, 1999; 11:319–326.
3.
O’LearyM., FowlerF., LenderkingW., BarberB., SagnierP., GuessH., et al.A brief male sexual function inventory for urology. Urology, 1995; 46:697–706.
4.
CappelleriJ.C., AlthofS.E., SiegelR.L., ShpilskyA., BellS.S., DuttaguptaS.Development and validation of the Self-Esteem and relationship (SEAR) questionnaire in erectile dysfunction. Int J Impo Res, 2004; 16:30–38.
5.
SwindleR.W., CameronA.E., LockhartD.C., RosenR.C.The Psychological and Interpersonal Relationship Scales: Assessing psychological and relationship outcomes with erectile dysfunction and it's treatment. Arch Sex Behav, 2004; 33:19–30.
6.
AlthofS.E., CortyE.W., LevineS.B., BurnettA.L., et al.EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology, 1999; 53:793–799.
7.
SpeckensA.E.M., HengeveldM.W., LycklamaA.N., Van HemertA.M., HawtonK.E.Discrimination between psychogenic and organic erectile dysfunction. J Psychosom Res, 1993; 37:135–145.
8.
SegravesK.A., SegravesR.T., SchoenbergH.W.Use of the sexual history to differentiate organic from psychogenic impotence. Arch Sex Behav, 1987; 16:125–137.
9.
JardinA, WagnerG, KhouryS, GiulianoF, Padma-NathanH, RosenR.Erectile Dysfunction. In: The 1st International Consultation on Erectile Dysfunction; 2000.
10.
LueT, GiulianoF, KhouryS, RosenR. In: The 2nd International Consultation on Sexual Dysfunctions; 2004.
11.
RalphD.J., McNicholasT.UK management guidelines for Erectile Dysfunction. BMJ, 2000; 321:499–503.
12.
GingellC., WrightP., BarnesT., et al.Guidance on the management of erectile dysfunction in Primary Care. Prescriber, 1999; 10(Suppl.):1–16.
13.
MaatmanT.J., MontagueD.K., MartinL.M.Erectile dysfunction in men with diabetes mellitus. Urology, 1987; 29:589–592.
14.
SairamK., KulinskayaE., BousteadG.B., HanburyD.C., McNicholasT.A.Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int, 2001; 88:68–71.
15.
AlbertiK.G., ZimmetP.Z.Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and Classification of Diabetes Mellitus. Provisional report of a WHO consultation. Diabet Med, 1998; 15:539–553.
16.
MannucciE., OgnibeneA., SposatoI., BrogiM., GalloriG., BardiniG., et al.Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabeto, 2003; 40:181–186.
17.
WeiM., MaceraC., DavisD., HornungC., NankinH., BlairS.Total cholesterol and high density lipoprotein cholesterol are important predictors of erectile dysfunction. Am J Epidemiol, 1994; 140:937–940.
18.
RoumeguereT., WespesE., CarpentierY., HoffmannP., SchulmanC.C.Erectile dysfunction is associated with a high prevalence of hyperlipidaemia and coronary heart disease risk. Eur Urol, 2003; 44:355–359.
19.
GovierF., McClureD., Kramer-LevienD.Endocrine screening of sexual dysfunction using free testosterone determination. J Urol, 1996; 156:405–408.
20.
BuvatJ., LemaireA.Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effectiveness strategy. J Urol, 1997; 158:1764–1767.
21.
QuamJ.P., KingB.F., JamesE.M., LewisR.W., BrakkeD.M., IlstrupD.M., et al.Duplex and color Doppler sonographic evaluation of vasculogenic impotence. AJR, 1989; 153:1141–1147.
22.
LueT.F., HricakH., MarichK.W.Vasculogic impotence evaluated by high-resolution ultrasonography and pulsed Doppler analysis. Radiology, 1985; 155:77.
23.
BensonC.B., VickersM.A.Sexual impotence caused by vascular disease: diagnosis with duplex sonography. AJR, 1989; 153:1149.
24.
KaracanI.Clinical value of nocturnal erection in the prognosis and diagnosis of impotence. Med Aspects Human Sex, 1970; 4:27.
25.
DjamillanM., StiefC.G., HartmannU., JonasU.Predictive value of real-time Rigiscan monitoring for the aetiology of organogenic impotence. J Urol, 1993; 149:1269–1271.
